- Investing.com
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Pivotal Data Ahead | September 2025 data release will be crucial, with investors eyeing safety data, efficacy in adolescents, and validation of skin frataxin as a surrogate endpoint |
Market Potential | Analyst targets range from $10 to $33, indicating significant upside potential despite current market undervaluation. Average price target is $19.50 |
Regulatory Landscape | FDA communication suggests a clear path to approval, with potential regulatory easements for rare diseases further bolstering Larimar's prospects |
Nomlabofusp's Promise | Larimar's flagship drug candidate targets the root cause of Friedreich's ataxia, potentially revolutionizing treatment for this rare genetic disorde |
Metrics to compare | LRMR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLRMRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.0x | −8.8x | −0.5x | |
PEG Ratio | 0.04 | −0.30 | 0.00 | |
Price / Book | 6.4x | 4.9x | 2.6x | |
Price / LTM Sales | - | 91.0x | 3.2x | |
Upside (Analyst Target) | 231.3% | 45.9% | 45.7% | |
Fair Value Upside | Unlock | −19.9% | 4.8% | Unlock |